Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT03939897
What this trial is testing

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic HER2-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Testing effectiveness (Phase 2)Study completedNCT05963997
What this trial is testing

Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 49
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Not applicableUnknownNCT05559528
What this trial is testing

BRaziLian outcomE for metAStatic breasT Cancer

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IV
Hospital do Coracao 300
Testing effectiveness (Phase 2)Looking for participantsNCT05190094
What this trial is testing

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Who this might be right for
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
International Cancer Research Group, United Arab Emirates 80
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Not applicableStudy completedNCT05034393
What this trial is testing

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Who this might be right for
Breast Cancer
Latin American Cooperative Oncology Group 308
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)Study completedNCT03703466
What this trial is testing

Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 72
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Ended earlyNCT05207709
What this trial is testing

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 61
Early research (Phase 1)Study completedNCT06570031
What this trial is testing

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer+1 more
Ono Pharmaceutical Co., Ltd. 46
Next Page